Results 11 to 20 of about 35,993 (244)

Platelet P2Y12 is involved in murine pulmonary metastasis. [PDF]

PLoS ONE, 2013
The involvement of platelets in tumor progression is well recognized. The depletion of circulating platelets or pharmacologic inhibitors of platelet activation decreases the metastatic potential of circulating tumor cells in metastasis mouse models.
Yanhua Wang, Yueping Sun, Ding Li, Lin Zhang, Kemin Wang, Yong Zuo, T Kent Gartner, Junling Liu   +7 more
doaj   +4 more sources

P2Y12 inhibitors for the neurointerventionalist

Interventional Neuroradiology, 2021
The use of antiplatelets is widespread in clinical practice. However, for neurointerventional procedures, protocols for antiplatelet use are scarce and practice varies between individuals and institutions. This is further complicated by the quantity of antiplatelet agents which differ in route of administration, dosage, onset of action, efficacy and ...
Borchert, Robin J, Simonato, Davide, R Hickman, Charlotte, Fuschi, Maurizio, Thibault, Lucie, Henkes, Hans, Fiorella, David, Tan, Benjamin Yq, Yeo, Leonard Ll, D Makalanda, Hegoda L, Wong, Ken, Bhogal, Pervinder   +11 more
openaire   +3 more sources

D121 Located within the DRY Motif of P2Y12 Is Essential for P2Y12-Mediated Platelet Function

International Journal of Molecular Sciences, 2022
Platelets are anucleate cells that mediate hemostasis. This occurs via a primary signal that is reinforced by secreted products such as ADP that bind purinergic receptors (P2Y1 and P2Y12) on the platelet surface. We recently identified a human subject, whom we termed platelet defect subject 25 (PDS25) with a platelet functional disorder associated with
Dangelmaier, Carol, Mauri, Benjamin, Patel, Akruti, Kunapuli, Satya P, Kostyak, John C   +4 more
openaire   +3 more sources

Coming safely to a stop : a review of platelet activity after cessation of antiplatelet drugs [PDF]

, 2015
Funding Isobel Ford is an employee of the University of Aberdeen. The research for the writing of this review received no specific grant from any funding agency in the public, commercial, or not-forprofit sectorsPeer ...
Ford, Isobel
core   +1 more source

Bivalirudin started during emergency transport for primary PCI. [PDF]

, 2013
BACKGROUND: Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI).
Berg, J. van den, Bernstein, D., Clayton, T., Clemmensen, P., Coste, P., Deliargyris, E.N., Eggink, G.J., et al., Goldstein, P., Grunsven, P. van, Hamm, C.W., Hamon, M., Hof, A. van't, Huber, K., Lapostolle, F., Nef, H., Nibbe, L., Orto, M. Campo dell', Pocock, S., Prats, J., Schuette, D., Soulat, L., Steg, P.G., Steinmetz, J., Verheugt, F.W.A., Zeymer, U.   +25 more
core   +1 more source

Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model [PDF]

, 2020
Alzheimer's disease, progressive supranuclear palsy and frontotemporal dementia are characterized by neuronal expression of aberrant tau protein, tau hyperphosphorylation (pTAU), tau aggregation and neurofibrillary tangle formation sequentially ...
Carmans, Sofie, de Vries, Helga E., Franssen, Marc, Kamermans, Alwin, Popovic, Marko, Roucourt, Bart, Schouten, Marijn, Sobrino, Tomás, van der Pol, Susanne M.A., van Olst, Lynn, Vandenbroucke, Roosmarijn, Verhaege, Daan, Wever, Dennis, Ytebrouck, Ellen   +13 more
core   +1 more source

Challenge in Predicting Persistence to P2Y12 Inhibitors: A Perspective From the ARTEMIS Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Premature discontinuation of P2Y12 inhibitor therapy has been associated with adverse cardiac events, which might be preventable by improving medication persistence. Current risk models have limited ability to predict patients at risk of P2Y12
Jennifer A. Rymer, Zachary K. Wegermann, Lisa A. Kaltenbach, Laura E. Webb, Eric D. Peterson, Tracy Y. Wang   +5 more
doaj   +1 more source

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

, 2018
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki, Farag, Mohamed, Gorog, Diana Adrienne, Spinthakis, Nikolaos   +3 more
core   +2 more sources

Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry. [PDF]

, 2020
BACKGROUND: The management of atrial fibrillation and flutter (AF) patients undergoing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution. In 2016, the Canadian Cardiovascular Society (CCS) published expert recommendations to
Boivin-Proulx, L-A, Camm, JA, Deneault-Marchand, A, Fox, KAA, Gobeil, F, Mansour, S, Matteau, A, Potter, BJ   +7 more
core   +1 more source

Microglial P2Y12 deficiency/inhibition protects against brain ischemia. [PDF]

PLoS ONE, 2013
Microglia are among the first immune cells to respond to ischemic insults. Triggering of this inflammatory response may involve the microglial purinergic GPCR, P2Y12, activation via extracellular release of nucleotides from injured cells.
Corey M Webster, Masaaki Hokari, April McManus, Xian Nan Tang, Hualong Ma, Rachid Kacimi, Midori A Yenari   +6 more
doaj   +1 more source